Condition: EGFR Positive Non-small Cell Lung Cancer · MET Amplification · Sponsor: Qingdao Central Hospital
Osimertinib combined with savolitinib in the treatment of EGFR mutated osimertinib resistant NSCLC with low copy number MET amplification There are unmet medical needs in patients who resist to to osimertinib; savolitinib plus osimertinib shows high response rate and prolong progression-free survival in high copy number MET amplification patients. This study is to explore the efficacy and safety of the combination of savolitinib and osimertinib in osimertinb resistant patients with low copy number MET amplification.
This description comes directly from the study's public registry record.
youxin Ji, md, phD · 1718865657 · kevinji78@yahoo.com
keke nie · 8618561857907 · niekeke@uor.edu.cn
Always discuss trial participation with your own doctor first.
| Qingdao Central Hospital | Qingdao, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07322783